
Customize View
Recently disclosed strategic alliances only (within the last two years)
Include Strategic Alliances for:Current subsidiaries



Strategic Alliances

Recently Disclosed Strategic Alliances
Strategic Alliance Name
Company Name
Primary Industry
Source
AbCellera Biologics Inc. (NasdaqGS:ABCL)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Life Sciences Tools and Services
AbCellera Biologics Inc. (NasdaqGS:ABCL) 2020 Form 424B4
Business Description: AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Abzena Limited
Gilead Sciences, Inc. (NasdaqGS:GILD)
Life Sciences Tools and Services
Abzena Limited - Form Doc
Business Description: Abzena Limited provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. Its technologies include antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation. The company provides phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine storm prior to it being progressed into clinical development. It also offers antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and ADCs. In addition, the company provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; peptide synthesis, modifications, and analytics; mammalian manufacturing, which cover cell line, process, and analytical development, as well as cell banking; peptide synthesis, modifications, and analytics; bioconjugates and ADCs manufacturing; and custom, library, HPAPI, and payload synthesis. Further, it offers full-time equivalent and protein/BioNMR services; and analytical solutions. It serves biopharmaceutical companies and academic groups. The company was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom. As of October 11, 2018, Abzena Limited was taken private.
Acerta Pharma B.V.
Forty Seven, Inc.
Pharmaceuticals
Forty Seven, Inc. 2020 Form 10-K
Business Description: Acerta Pharma B.V. engages in the research, discovery, and development of therapeutics and new molecular entities for the treatment of hematology and cancer. The company was founded in 2013 and is based in Oss, the Netherlands. Acerta Pharma B.V. operates as a subsidiary of AstraZeneca PLC
Appia Bio, Inc.
Kite Pharma, Inc.
Biotechnology
Gilead Sciences, Inc. (NasdaqGS:GILD) 2022 Form 10-K
Business Description: Appia Bio, Inc. focuses on developing engineered allogeneic cell therapies across an array of indications with a technology platform that increases therapeutic options and availability for patients. The company’s technology leverages the biology of lymphocyte development with chimeric antigen receptor and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs). Appia Bio, Inc. was incorporated in 2020 and is based in Culver City, California.
Arcellx, Inc. (NasdaqGS:ACLX)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Gilead Sciences, Inc. (NasdaqGS:GILD) 2023 Form 10-K
Business Description: Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company’s lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Arcus Biosciences, Inc. (NYSE:RCUS)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Gilead Sciences, Inc. (NasdaqGS:GILD) 2023 Form 10-K
Business Description: Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company’s preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
Ares Trading SA
Forty Seven, Inc.
Biotechnology
Forty Seven, Inc. 2020 Form 10-K
Business Description: Ares Trading SA manufactures biotechnology products for therapeutic areas. It provides human menopausal gonadotrophin hormones. The company’s Pergonal, is a natural purified product extracted from the urine of postmenopausal women. Ares Trading SA has a collaboration with F-star Therapeutics, Inc. The company was founded in 1987 and is based in Aubonne, Switzerland. Ares Trading SA operates as a subsidiary of Merck Serono S.A.
Biocartis Group NV (ENXTBR:BCART)
Kite Pharma, Inc.
Health Care Equipment
Key DevelopmentClient Announcements Jun-01-2019
Business Description: Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
Biotoscana Investments S.A.
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Biotoscana Investments S.A. 2019 Form 
Business Description: Biotoscana Investments S.A., a biopharmaceutical company, through its subsidiaries, develops, manufactures, and commercializes medicines for treating truly unmet medical needs. It also engages in the purchase, sale, distribution, importation, exportation, and trade in pharmaceuticals, para-pharmaceuticals, and chemical products. The company offers drugs for the treatment of infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation, orphan/rare diseases, and others. The company was formerly known as Biotoscana Investments & CY S.C.A. and changed its name to Biotoscana Investments S.A. Biotoscana Investments S.A. was incorporated in 2011 and is headquartered in Montevideo, Uruguay. Biotoscana Investments S.A. operates as a subsidiary of 1178991 Canada Inc.
bluebird bio, Inc. (NasdaqGS:BLUE)
Forty Seven, Inc.
Biotechnology
Forty Seven, Inc. 2020 Form 10-K
Business Description: bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Clovis Oncology, Inc.
Immunomedics, Inc.
Biotechnology
Clovis Oncology, Inc. 2020 Form 10-K
Business Description: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on June 16, 2023.
DarwinHealth, Inc.
HOOKIPA Pharma Inc. (NasdaqGS:HOOK)
Biotechnology
HOOKIPA Pharma Inc. (NasdaqGS:HOOK) 2023 Form 10-K
Business Description: DarwinHealth, Inc. is a biotechnology company. It is based in New York, New York.
DRAGONFLY Therapeutics, Inc.
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Gilead Sciences, Inc. (NasdaqGS:GILD) 2023 Form 10-K
Business Description: DRAGONFLY Therapeutics, Inc. discovers, develops, and commercializes therapies that uses its novel bispecific antibody technology to harness the body's innate immune system to bring breakthrough treatments for patients. It also operates its proprietary platform that enhances immunotherapy. DRAGONFLY Therapeutics, Inc. has strategic relationship with Celgene Corporation and Merck. DRAGONFLY Therapeutics, Inc. has a collaboration with AbbVie. The company was incorporated in 2015 and is based in Waltham, Massachusetts.
Eisai Co., Ltd. (TSE:4523)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Pharmaceuticals
Key DevelopmentStrategic Alliances Dec-24-2019
Business Description: Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Eli Lilly and Company (NYSE:LLY)
Forty Seven, Inc.
Pharmaceuticals
Forty Seven, Inc. 2020 Form 10-K
Business Description: Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Evoq Therapeutics LLC
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Key DevelopmentClient Announcements Jan-03-2023
Business Description: Evoq Therapeutics LLC operates as a biotechnology company. It is based in the United States.
F. Hoffmann-La Roche Ltd
Hookipa Biotech AG
Biotechnology
HOOKIPA Pharma Inc. (NasdaqGS:HOOK) 2023 Form 10-K
Business Description: F. Hoffmann-La Roche Ltd, a biotechnology company, discovers and develops in-vitro diagnostics and medicines for patients worldwide. The company engages in the discovery, development, and manufacturing of in-vitro tests for the diagnosis of various diseases, including cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; development and manufacturing of diagnostic instruments; and development of a portfolio of digital solutions for laboratories, physicians, and patients. It also provides pharmaceutical products for the treatment of anemia, cancer, dermatology, hemophilia, infectious diseases, inflammatory and autoimmune diseases, neurological disorders, ophthalmology, and respiratory disorders, as well as products for the prevention of organ rejection in patients receiving kidney, heart, or liver transplants. The company was founded in 1896 and is based in Basel, Switzerland. F. Hoffmann-La Roche Ltd operates as a subsidiary of Roche Holding AG.
Galapagos NV (ENXTAM:GLPG)
Gilead Biopharmaceutics Ireland UC
Biotechnology
Galapagos NV (ENXTAM:GLPG) 2020 Form 20-F
Business Description: Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Genentech, Inc.
Forty Seven, Inc.
Biotechnology
Forty Seven, Inc. 2020 Form 10-K
Business Description: Genentech, Inc. operates as a biotechnology company that discovers and develops medicines for people with diseases. It offers medicines for the areas of oncology, immunology, neuroscience, metabolism, infectious disease, and ophthalmology. The company was formerly known as Genentech Delaware, Inc. and changed its name to Genentech, Inc. in January 1987. The company was founded in 1976 and is based in South San Francisco, California with additional offices in Hillsboro,Oregon; Vacaville and Oceanside, California. Genentech, Inc. operates as a subsidiary of Roche Holding AG.
Gilead Sciences, Inc. (NasdaqGS:GILD)
Hookipa Biotech AG
Biotechnology
Key DevelopmentClient Announcements Jan-13-2006
Business Description: Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc. (NasdaqGS:GILD)
HOOKIPA Pharma Inc. (NasdaqGS:HOOK)
Biotechnology
HOOKIPA Pharma Inc. (NasdaqGS:HOOK) 2023 Form 10-K
Business Description: Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Glympse Bio, Inc. (Acquired)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Health Care Equipment
Key DevelopmentStrategic Alliances Oct-28-2019
Business Description: As of August 9, 2023, Glympse Bio, Inc. was acquired by Sunbird Bio, Inc. Glympse Bio, Inc. develops modular nanoparticle sensors to create diagnostics for fibrosis, cancer, immunology, and infectious diseases and monitors drug responses. It uses engineered diagnostic agents that interrogate the body for certain disease states and then carry the message to the urine for analysis. The company provides Glympse Inside, a pan-disease product engine that aims to transform disease monitoring and treatment response. Glympse Bio, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Hoffmann-La Roche Inc.
Hookipa Biotech AG
Pharmaceuticals
HOOKIPA Pharma Inc. (NasdaqGS:HOOK) 2023 Form 10-K
Business Description: Hoffmann-La Roche Inc. manufactures drugs and vitamin products. It offers drugs and in-vitro diagnostics for cancer and transplantation, and therapeutic products for cancer, neuroscience, infectious diseases, immunology, cardiovascular, and metabolism diseases. The company was formerly known as Roche Chemical Works Inc. and changed its name to Hoffmann-La Roche Inc. in January 1929. The company was founded in 1905 and is based in Little Falls, New Jersey. Hoffmann-La Roche Inc. operates as a subsidiary of Roche Holding AG.
Hookipa Biotech AG
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Key DevelopmentStrategic Alliances Feb-15-2022
Business Description: Hookipa Biotech AG, a clinical stage biotechnology company, develops active immunization therapies for infectious diseases and oncology. The company’s Vaxwave platform is focused on the development of prophylactic vaccines to prevent infectious diseases; and TheraT platform enables the development of immuno-oncology therapies and therapeutic vaccines. Its product pipeline includes HB-101 Vaxwave, a vaccine against cytomegalovirus; Research ID1 Vaxwave for the treatment of hepatitis-B; HB-201 Heterologous TheraT for the treatment of human papilloma virus (HPV) and related head and neck cancers; HB-301 Heterologous TheraT for the treatment of prostate cancer; and Research IO1 TheraT compound. The company has strategic alliance with ABL EUROPE S.A.S. Hookipa Biotech AG was founded in 2011 and is based in Vienna, Austria. Hookipa Biotech AG operates as a subsidiary of HOOKIPA Pharma Inc.
Humanigen, Inc. (OTCPK:HGEN)
Kite Pharma, Inc.
Biotechnology
Humanigen, Inc. (OTCPK:HGEN) 2020 Form S-1
Business Description: Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
ImClone LLC
Forty Seven, Inc.

Forty Seven, Inc. 2020 Form 10-K
Business Description: ImClone LLC operates as a subsidiary of Eli Lilly and Company.
ImmunoGen, Inc. (NasdaqGS:IMGN)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Key DevelopmentStrategic Alliances Dec-09-2022
Business Description: ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRα), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRα product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Johnson Matthey Plc (LSE:JMAT)
Immunomedics, Inc.
Specialty Chemicals
Johnson Matthey Plc (LSE:JMAT) - Form Doc
Business Description: Johnson Matthey Plc engages in the clean air, catalyst and hydrogen technology, and platinum group metals (PGM) service businesses in the United Kingdom, Germany, rest of Europe, the United States, rest of North America, China, rest of Asia, and internationally. It operates through five segments: Clean Air, PGM Services, Catalyst Technologies, Hydrogen Technologies, and Value Businesses. The Clean Air segment provides catalysts for emission control after-treatment systems to reduce harmful emissions from cars, other light duty vehicles, trucks, buses, and non-road equipment powered by internal combustion engines. The PGM Services segment enables the energy transition through providing circular solutions as demand for critical materials. This segment also offers PGM refining and recycling, and trading services; other precious metal products; and PGM chemicals, industrial products, and catalysts. The Catalyst Technologies segment is involved in decarbonization of chemical and fuel value chains. This segment also provides speciality catalysts and additives; process technology licenses; and engineering design services. The Hydrogen Technologies segment offers catalyst coated membranes that are a critical component for fuel cells and electrolysers. The Value Businesses segment business portfolio includes precious metal pastes and enamels, and battery systems and products for devices used in medical procedures; and detection and measurement solutions. The company was formerly known as Johnson & Cock and changed its name to Johnson Matthey Plc in 1851. Johnson Matthey Plc was founded in 1817 and is based in London, the United Kingdom.
Jounce Therapeutics, Inc.
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Gilead Sciences, Inc. (NasdaqGS:GILD) 2023 Form 10-K
Business Description: Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. As of May 3, 2023, Jounce Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Pharmaceuticals
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) 2019 Form 10-K
Business Description: Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
MacroGenics, Inc. (NasdaqGS:MGNX)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Gilead Sciences, Inc. (NasdaqGS:GILD) 2023 Form 10-K
Business Description: MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Merck & Co., Inc. (NYSE:MRK)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Pharmaceuticals
Gilead Sciences, Inc. (NasdaqGS:GILD) 2023 Form 10-K
Business Description: Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck & Co., Inc. (NYSE:MRK)
HOOKIPA Pharma Inc. (NasdaqGS:HOOK)
Pharmaceuticals
HOOKIPA Pharma Inc. (NasdaqGS:HOOK) 2023 Form 10-K
Business Description: Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck KGaA (XTRA:MRK)
Forty Seven, Inc.
Pharmaceuticals
Forty Seven, Inc. 2020 Form 10-K
Business Description: Merck KGaA operates as a science and technology company in Germany. The company’s Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company’s Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
Merck Sharp & Dohme LLC
Gilead Sciences, Inc. (NasdaqGS:GILD)
Pharmaceuticals
Gilead Sciences, Inc. (NasdaqGS:GILD) 2023 Form 10-K
Business Description: Merck Sharp & Dohme LLC manufactures and distributes vaccines, prescription products, oncology products, consumer products, animal health products, and biologic therapies for customers worldwide. The company offers injections, inhalation powders, inhalation aerosols, tablets, oral solutions for oral use, capsules, creams, lotions, ointments, implants, chewable tablets, nasal sprays, transdermal infusion systems, etonogestrel/ethinyl estradiol vaginal rings, oral granules, and suspensions. It sells its products through authorized distributors. Merck Sharp & Dohme LLC was formerly known as Merck Sharp & Dohme Corp. and changed its name to Merck Sharp & Dohme LLC in May 2022. The company was founded in 1891 and is based in Rahway, New Jersey. Merck Sharp & Dohme LLC operates as a subsidiary of Merck & Co., Inc.
Nektar Therapeutics (NasdaqGS:NKTR)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Pharmaceuticals
Nektar Therapeutics (NasdaqGS:NKTR) 2020 Form 10-K
Business Description: Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.
Novo Nordisk A/S (CPSE:NOVO B)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Pharmaceuticals
Key DevelopmentStrategic Alliances Mar-18-2021
Business Description: Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Nurix Therapeutics, Inc. (NasdaqGM:NRIX)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Nurix Therapeutics, Inc. (NasdaqGM:NRIX) 2021 Form S-1
Business Description: Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Oncora Medical, Inc.
Tmunity Therapeutics, Inc.
Health Care Technology
Key DevelopmentClient Announcements Nov-04-2019
Business Description: Oncora Medical, Inc. develops an analytics platform that helps radiation oncologists to use data to provide the care for cancer patients. It provides plug-and-play data extraction tools to integrate clinical information from electronic medical record systems, treatment planning software, and oncology information systems into database; allows physicians to make personalized treatment recommendations for their patients using historical data and predictive analytics; and enables physicians to apply machine learning algorithms to their data to gain information about patient outcomes. Oncora Medical, Inc. was incorporated in 2015 and is based in Philadelphia, Pennsylvania.
Ono Pharmaceutical Co., Ltd. (TSE:4528)
Forty Seven, Inc.
Pharmaceuticals
Forty Seven, Inc. 2020 Form 10-K
Business Description: Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs. The company was founded in 1717 and is headquartered in Osaka, Japan.
Pionyr Immunotherapeutics Inc.
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Gilead Sciences, Inc. (NasdaqGS:GILD) 2023 Form 10-K
Business Description: Pionyr Immunotherapeutics Inc. develops cancer immunotherapies that target the tumor microenvironment to enhance the body's antitumor immunity. The company's immunotherapies enhance the immune system's anti-tumor response by altering the cellular infiltrate of the tumor microenvironment which enables patients to combat cancer particularly in combination with checkpoint inhibitors. The company was formerly known as Precision Immune Inc. and changed its name to Pionyr Immunotherapeutics Inc. in February 2017. The company was incorporated in 2015 and is based in South San Francisco, California. As of August 4, 2023, Pionyr Immunotherapeutics Inc. operates as a subsidiary of Ikena Oncology, Inc.
Publicis Groupe S.A. (ENXTPA:PUB)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Advertising
Publicis Groupe S.A. (ENXTPA:PUB) 2020 Form 
Business Description: Publicis Groupe S.A. provides marketing, communications, and digital business transformation services in North America, Europe, the Asia Pacific, Latin America, Africa, and the Middle East. The company offers advisory services for brand strategy, and repositioning and their identity under the Publicis Worldwide, Saatchi & Saatchi, Leo Burnett, Marcel, Fallon, and BBH brands; online advertising services under the Razorfish and Moxie brand names; crisis communications, press relations, public affairs, institutional relations, financial communications, and strategy management services; media consulting, planning, and buying services; performance marketing services; and e-commerce services. It also designs and delivers brand content for various channels, such as television, print, radio, cinema, and billboards, as well as digital, including display and social networks under the Prodigious, Harbor, and The Pub brand names. In addition, the company operates Epsilon PeopleCloud, a unified data and technology platform; and Publicis Sapient, a technological, digital, and consulting platform. Further, it provides healthcare communication services under the Digitas Health, Publicis Health Media, and Saatchi & Saatchi Wellness brands for the healthcare and well-being sectors. It serves clients in the automotive, retail, financial services, consumer products, and media sectors. Publicis Groupe S.A. was founded in 1926 and is headquartered in Paris, France.
Renown Health
Gilead Sciences, Inc. (NasdaqGS:GILD)
Health Care Facilities
Key DevelopmentClient Announcements Jul-11-2019
Business Description: Renown Health is a health care facilities company. It was formerly known as Washoe Health System and changed its name to Renown Health in January 2006. The company is based in Nevada.
Roche Holding AG (SWX:ROG)
Immunomedics, Inc.
Pharmaceuticals
Key DevelopmentStrategic Alliances Jul-13-2020
Business Description: Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT)
Forty Seven, Inc.
Biotechnology
Forty Seven, Inc. 2020 Form 10-K
Business Description: Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.
Royalty Pharma plc (NasdaqGS:RPRX)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Pharmaceuticals
Royalty Pharma plc (NasdaqGS:RPRX) 2020 Form S-1
Business Description: Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc (NasdaqGS:RPRX)
Immunomedics, Inc.
Pharmaceuticals
Royalty Pharma plc (NasdaqGS:RPRX) 2020 Form S-1
Business Description: Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Sangamo Therapeutics, Inc. (NasdaqGS:SGMO)
Kite Pharma, Inc.
Biotechnology
Sangamo Therapeutics, Inc. (NasdaqGS:SGMO) 2020 Form 10-K
Business Description: Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Satcher Health Leadership Institute
Gilead Sciences, Inc. (NasdaqGS:GILD)

Key DevelopmentClient Announcements May-26-2021
Business Description: There is no business description for this company.
Schrödinger, Inc. (NasdaqGS:SDGR)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Health Care Technology
Schrödinger, Inc. (NasdaqGS:SDGR) 2020 Form 424B4
Business Description: Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)
Kite Pharma, Inc.
Pharmaceuticals
Gilead Sciences, Inc. (NasdaqGS:GILD) 2022 Form 10-K
Business Description: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, anti-infection, API’s and intermediate, metabolism, alimentary system, cardiovascular and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services, and investment management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Shoreline Biosciences, Inc.
Kite Pharma, Inc.
Biotechnology
Gilead Sciences, Inc. (NasdaqGS:GILD) 2022 Form 10-K
Business Description: Shoreline Biosciences, Inc. develops cellular immunotherapies based on induced pluripotent stem cells (iPSCs). The company offers iPSC-derived natural killer cells and macrophage cell therapies for cancer and other serious diseases. The company was incorporated in 2020 and is based in San Diego, California.
Tango Therapeutics, Inc. (NasdaqGM:TNGX)
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Gilead Sciences, Inc. (NasdaqGS:GILD) 2023 Form 10-K
Business Description: Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Tizona Therapeutics, Inc.
Gilead Sciences, Inc. (NasdaqGS:GILD)
Biotechnology
Gilead Sciences, Inc. (NasdaqGS:GILD) 2023 Form 10-K
Business Description: Tizona Therapeutics, Inc. develops immunotherapies. Its products include Anti-CCR4 antibody for the treatment of cancer, IL-35 antagonists for the treatment of cancer, and IL-35 agonists for the treatment of autoimmune diseases. The company was incorporated in 2014 and is based in South San Francisco, California.
*denotes proprietary relationship